Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services
Vaxcyte (NASDAQ:PCVX), a clinical-stage vaccine company, has announced a significant manufacturing agreement with Thermo Fisher Scientific to establish fill-finish commercial manufacturing capabilities in Greenville, North Carolina. The long-term agreement, valued at up to $1 billion, focuses on manufacturing Vaxcyte's broad-spectrum pneumococcal conjugate vaccines (PCVs).
This strategic initiative represents a major expansion of Vaxcyte's domestic manufacturing capacity and strengthens its U.S. commercial supply chain. The partnership aligns with the company's commitment to domestic biomanufacturing and aims to enhance commercial readiness while investing in American infrastructure and employment.
Vaxcyte (NASDAQ:PCVX), azienda di vaccini in fase clinica, ha annunciato un importante accordo di produzione con Thermo Fisher Scientific per istituire capacità di riempimento e rifinitura per la produzione commerciale a Greenville, North Carolina. L’accordo a lungo termine, del valore fino a 1 miliardo di dollari, riguarda la produzione dei vaccini coniugati pneumococcici a spettro ampio (PCV) di Vaxcyte. Questa iniziativa strategica rappresenta una notevole espansione della capacità di produzione domestica e rafforza la sua catena di fornitura commerciale statunitense. L’alleanza è in linea con l’impegno dell’azienda per la bioproduzione domestica e mira a migliorare la prontezza commerciale, investendo in infrastrutture e occupazione americane.
Vaxcyte (NASDAQ:PCVX), una empresa de vacunas en fase clínica, ha anunciado un acuerdo de fabricación significativo con Thermo Fisher Scientific para establecer capacidades de llenado y envasado para fabricación comercial en Greenville, Carolina del Norte. El acuerdo a largo plazo, de hasta 1.000 millones de dólares, se centra en la fabricación de las vacunas conjugadas neumocócicas (PCV) de amplio espectro de Vaxcyte. Esta iniciativa estratégica representa una gran expansión de la capacidad de fabricación nacional de Vaxcyte y fortalece su cadena de suministro comercial en EE. UU. La asociación se alinea con el compromiso de la empresa con la bioproducción doméstica y busca mejorar la preparación comercial invirtiendo en infraestructuras y empleo estadounidenses.
Vaxcyte (NASDAQ:PCVX), 임상 단계의 백신 회사는 Thermo Fisher Scientific과 중요한 제조 계약을 발표했고 노스캐롤라이나주 그리놀빌에서 완충 및 마감(필링-피니시) 상업용 제조 역량을 구축합니다. 최대 10억 달러 규모의 장기 계약으로, Vaxcyte의 광범위한 스펙트럼 폐구균 결합 백신(PCV) 제조에 집중합니다. 이 전략적 이니셔티브는 미국 내 제조 능력을 크게 확장하고 미국 내 상업적 공급망을 강화합니다. 이 파트너십은 국내 바이오제조에 대한 회사의 약속과 일치하며, 상업적 준비성을 향상시키는 한편 미국의 인프라 및 고용에 투자하는 것을 목표로 합니다.
Vaxcyte (NASDAQ:PCVX), société de vaccins en phase clinique, a annoncé un accord de fabrication important avec Thermo Fisher Scientific pour établir des capacités de remplissage et de finition pour la fabrication commerciale à Greenville, en Caroline du Nord. Cet accord à long terme, d’une valeur pouvant atteindre 1 milliard de dollars, porte sur la fabrication des vaccins conjugués antipneumococciques (PCV) à large spectre de Vaxcyte. Cette initiative stratégique représente une expansion majeure de la capacité de fabrication nationale de Vaxcyte et renforce sa chaîne d’approvisionnement commerciale américaine. Le partenariat s’aligne sur l’engagement de l’entreprise en faveur de la bioproduction domestique et vise à améliorer la préparation commerciale tout en investissant dans les infrastructures et l’emploi américains.
Vaxcyte (NASDAQ:PCVX), ein klinischer Impfstoffhersteller, hat eine bedeutende Fertigungsvereinbarung mit Thermo Fisher Scientific bekannt gegeben, um in Greenville, North Carolina, Fertigfüll- und kommerzielle Fertigungskapazitäten aufzubauen. Die langfristige Vereinbarung, deren Wert bis zu 1 Milliarde US-Dollar beträgt, konzentriert sich auf die Herstellung von Vaxcytes breitwirksamen Pneumokokken-Konjugatimpfstoffen (PCV). Diese strategische Initiative stellt eine bedeutende Erweiterung der heimischen Fertigungskapazität von Vaxcyte dar und stärkt seine US-amerikanische kommerzielle Lieferkette. Die Partnerschaft steht im Einklang mit dem Engagement des Unternehmens für inländische Bioproduktion und zielt darauf ab, die Kommerzbereitschaft zu verbessern, während in Infrastruktur und Beschäftigung in den USA investiert wird.
Vaxcyte (الإدراج في ناسداك: PCVX)، وهي شركة لقاحات في مرحلة التجارب السريرية، أعلنت عن اتفاق تصنيع هام مع Thermo Fisher Scientific لإقامة قدرات تصنيع تعبئة وتغليف تجارية في غرينفيل، نورث كارولينا. الصفقة طويلة الأجل، التي تصل قيمتها إلى مليار دولار أمريكي، تركز على تصنيع لقاحات المكورات الرئوية المقترنة واسعة النطاق (PCV) من Vaxcyte. تمثل هذه المبادرة الاستراتيجية توسعاً كبيراً في قدرة التصنيع المحلية لشركة Vaxcyte وتقوي سلسلة التوريد التجارية في الولايات المتحدة. تتوافق الشراكة مع التزام الشركة بالتصنيع الحيوي المحلي وتهدف إلى تعزيز الجاهزية التجارية مع الاستثمار في البنية التحتية الأمريكية وفرص العمل.
Vaxcyte（纳斯达克：PCVX），一家临床阶段疫苗公司，宣布与 Thermo Fisher Scientific 达成重要的制造协议，在北卡罗来纳州格林维尔建立填充和成品化的商业化制造能力。长期协议，价值最高可达10亿美元，聚焦于制造 Vaxcyte 的广谱肺炎球菌结合疫苗（PCV）。这一战略举措标志着 Vaxcyte 国内制造能力的重大扩张，并强化其在美国的商业供应链。该伙伴关系符合公司对国内生物制造的承诺，旨在提升商业就绪度，同时投资于美国的基础设施和就业。
- Long-term manufacturing agreement worth up to $1 billion demonstrates significant scale and commitment
- Strategic expansion of domestic manufacturing capacity enhances supply chain control
- Partnership with industry leader Thermo Fisher Scientific provides reliable manufacturing expertise
- Investment strengthens U.S.-based operations and commercial readiness
- Significant financial commitment may impact cash resources
- Execution risks associated with scaling up manufacturing operations
New Agreement with Thermo Fisher Scientific Expands Domestic Capacity to Support Future Commercial Manufacturing of Vaxcyte’s Broad-Spectrum Pneumococcal Conjugate Vaccine Candidates
SAN CARLOS, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced a new agreement with Thermo Fisher Scientific Inc., the world leader in serving science, to bring additional fill-finish commercial manufacturing for Vaxcyte’s broad-spectrum pneumococcal conjugate vaccines (PCVs) to the United States.
As a key element of Vaxcyte’s long-term U.S. commercial supply strategy, Thermo Fisher will provide custom commercial fill-finish capacity for the Company’s broad-spectrum PCVs at its Greenville, North Carolina facility. The initiative, including both manufacturing and related services, signifies a long-term U.S. commercial manufacturing commitment for Vaxcyte representing up to
“The decision to significantly expand our fill-finish manufacturing capacity in the United States represents an effort to expand our end-to-end supply strategy and align with the increasing focus on domestic biomanufacturing,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. “By scaling our fill-finish operations in North Carolina, we’re strengthening our U.S. supply chain, enhancing commercial readiness and deepening our investment in American innovation, infrastructure and jobs — all in service of our mission to deliver high-fidelity vaccines that protect against serious infectious diseases.”
About Vaxcyte
Vaxcyte is a U.S.-headquartered vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s lead vaccine candidate is VAX-31, a 31-valent PCV candidate advancing to a Phase 3 adult clinical program and being evaluated in a Phase 2 infant clinical program. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. The Company’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella. For more information, visit www.vaxcyte.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements related to the future commercial supply of Vaxcyte’s PCV candidates; the anticipated benefits, scope and scale of Vaxcyte’s agreement with Thermo Fisher Scientific; potential benefits of Vaxcyte’s carrier-sparing platform and PCV candidates; and other statements that are not historical fact. The words “anticipate,” “believe,” “could,” “expect,” “intend,” “may,” “on track,” “potential,” “should,” “would” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on Vaxcyte’s current expectations and actual results and timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, including, without limitation, risks related to Vaxcyte’s product development programs, including development timelines, success and timing of chemistry, manufacturing and controls and related manufacturing activities, potential delays or inability to obtain and maintain required regulatory approvals for its vaccine candidates, and the risks and uncertainties inherent with preclinical and clinical development processes; the success, cost and timing of all development activities and clinical trials; sufficiency of cash and other funding to support Vaxcyte’s development programs and other operating expenses; the performance of third-party partners; and general market and economic conditions. These and other risks are described more fully in Vaxcyte’s filings with the Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025 or in other documents Vaxcyte subsequently files with or furnishes to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date, and readers should not rely upon the information in this press release as current or accurate after its publication date. Vaxcyte undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations. Readers should not rely upon the information in this press release as current or accurate after its publication date.
Contacts:
Media:
Patrick Ryan, Executive Director, Corporate Affairs
Vaxcyte, Inc.
415-606-5135
media@vaxcyte.com
Investors:
Jeff Macdonald, Executive Director, Investor Relations
Vaxcyte, Inc.
917-371-0940
investors@vaxcyte.com
FAQ
What is the value of Vaxcyte's (PCVX) manufacturing agreement with Thermo Fisher?
Where will Vaxcyte's (PCVX) new manufacturing facility be located?
What products will be manufactured at Vaxcyte's new facility?
Why did Vaxcyte (PCVX) choose to establish manufacturing in North Carolina?
Who is Vaxcyte partnering with for the manufacturing facility?
